Reimbursed Care Access in Cayman Islands
The Cayman Islands maintains strict drug control under its Misuse of Drugs legislation; most classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, ibogaine, ayahuasca) are treated as controlled substances with no authorised medical use outside approved research. Ketamine is available and used in medical settings (primarily as an anesthetic) but psychedelic/psychiatric uses of ketamine remain off‑label and are not covered by public reimbursement. There is no publicly available evidence of local regulatory approval or public reimbursement for esketamine (Spravato) in the Cayman Islands; medicinal cannabis is the notable exception to total prohibition (separately regulated).
Psilocybin
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
MDMA
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
Esketamine
There is no public record in Cayman Islands government sources of a national regulatory approval or public reimbursement listing for esketamine (Spravato) as of the most recent Cayman Islands legislative/health publications; specialist pharmaceuticals with novel psychiatric indications (such as esketamine) are generally handled through private importation channels or within hospital procurement if clinically justified, but these are not covered by a public reimbursement program. The Cayman Islands Health Services Authority is the public hospital authority that administers in‑country hospital medicines and anesthesia services (ketamine is used in hospital settings), which implies that traditional ketamine as an anesthetic is available in public care but newer psychiatric‑label products require separate procurement/authorization. # #
Ketamine
Ketamine is an established medication for anesthesia and emergency medicine in Cayman Islands health services and is used within hospital settings for those indications; its use for psychiatric indications (e.g., subanesthetic infusions for depression) would be off‑label, clinician‑directed, and handled case‑by‑case without routine public reimbursement. Public hospital services (Health Services Authority / Cayman Islands Hospital) provide anesthesia and critical care where ketamine is routinely used, indicating licensed medical access for licensed indications; however, there is no evidence of a formal public reimbursement pathway for ketamine when used specifically as a psychiatric treatment rather than as an anesthetic or analgesic. # #
DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
5-MeO-DMT
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. #
Ibogaine
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Internationally ibogaine’s legal status varies, but in the Cayman Islands there is no authorised medical pathway for ibogaine outside approved research. #
Ayahuasca
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing controlled tryptamines (DMT/psilocin) fall under the Misuse of Drugs framework. #
Mescaline
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Peyote/mescaline compounds and analogues are controlled in jurisdictions with schedules like Cayman’s Misuse of Drugs Law. #
2C-X
Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Substituted phenethylamines (2C family) are routinely scheduled by national Misuse of Drugs legislation. #